WuXi AppTec
101 Morgan Lane
Plainsboro
New Jersey
08536
United States
Tel: 609-606-6616
Website: http://www.wuxiapptec.com/
Email: Julia.nuesch@wuxiapptec.com
About WuXi AppTec
Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.
The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services.
WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 14,000 employees and 6 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services, WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.
108 articles with WuXi AppTec
-
SAMDI Tech Provides 1+ Million Compounds Through WuXi Partnership for Drug Candidate Screening
2/26/2019
SAMDI Tech Inc., the industry’s leading provider of label-free drug discovery solutions, now has well over 1 million compounds in its small molecule screening collection, in part through a partnership with WuXi AppTec’s LabNetwork, a global e-commerce platform connecting chemistry and research communities worldwide.
-
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
-
WuXi Biologics and Oxford BioTherapeutics Expand Partnership With 5 More Antibody Compounds
12/11/2018
WuXi Biologics, a Shanghai, China-based contract research organization focused on biologics, announced it was expanding its existing collaboration and licensing deals with UK-based Oxford BioTherapeutics (OBT). -
WuXi AppTec Expands Site in California for Pharmaceutical R&D Services
12/10/2018
WuXi AppTec's newly expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including phase I GMP manufacturing.
-
At its San Diego site, the company plans to establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D, which will also include Phase I GMP manufacturing.
-
Schrödinger and WuXi AppTec Announce the Launch of Faxian Therapeutics to Enable Accelerated Drug Discovery
10/30/2018
The new venture will leverage the precision molecular design platforms developed by Schrödinger and accelerate them through partnership with the world-class lead optimization services provided by WuXi AppTec.
-
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
-
Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.
-
Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections
10/4/2018
Acurx and WuXi AppTec enter collaboration to advance Acurx's pipeline of novel DNA polymerase-inhibiting antibiotic candidates.
-
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
-
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
-
Biotech Movers and Shakers Aug. 27
8/27/2018
Who made a splash in the biotech world this week? Here are some notable people. -
WuXi AppTec Research Service Division and Cyclica Collaborate to Drive Polypharmacology in Drug Discovery Through AI-Augmented Technologies
8/16/2018
WuXi AppTec Research Service Division and Cyclica are pleased to announce a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology, while further evolving Cyclica’s biophysics and AI-augmented platform.
-
Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.
-
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
-
Boston, New York, San Diego and San Francisco are the typical spots that people refer to when they think about biotech hotspots in the United States. But don’t discount New Jersey.
-
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
-
Chinese companies and investors continue to flex their financial muscles with a series of deals this week that highlight the continued growing impact that country is having on the global pharmaceutical and biotech landscape.
-
Juvenescence closed on an oversubscribed Series A financing worth $50 million. It brings the company’s total fundraising to $63 million.The company is focused on developing therapies to increase healthy human longevity.
-
Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationsh...
5/24/2018
Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.